Opendata, web and dolomites

VETEX SIGNED

Deep Vein Thrombosis; A Paradigm Change in Treatment through Drug-Free Clot Removal

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VETEX project word cloud

Explore the words cloud of the VETEX project. It provides you a very rough idea of what is the project "VETEX" about.

clinical    involve    completion    prevent    causing    dvt    risks    deep    stage    interventions    entry    plan    untreated    attack    alone    hospital    healthcare    coming    radically    hours    disease    mortality    rate    platform    team    pulmonary    amputation    approvals    larger    patients    regulatory    thrombosis    embolism    witness    clot    market    economics    ireland    extension    volumes    poor    cardiovascular    icu    therapy    vein    24    extremely    stroke    last    swelling    therapies    stays    removes    drugs    segment    2m    providers    15    ulceration    complications    upper    steadily    away    600m    syndrome    medical    50    trial    72    expedited    duty    recurrence    left    device    strategy    busting    remove    usually    helps    veins    diagnosed    clots    risk    inefficiencies    heavier    thrombolytic    thrombotic    securing    bleeding    form    trend    treatment    rates    limb    heart    expensive    3rd    freeflow    occulsive    vetex    opportunity    anticoagulation    2021    commercialise    post    30    chronic    skills    breaking   

Project "VETEX" data sheet

The following table provides information about the project.

Coordinator
VETEX MEDICAL LIMITED 

Organization address
address: 218 BUSINESS INNOVATION CENTRE, NUIG
city: GALWAY
postcode: H91 FC85
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙550˙920 €
 EC max contribution 2˙485˙644 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETEX MEDICAL LIMITED IE (GALWAY) coordinator 2˙485˙644.00

Map

 Project objective

Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.

Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.

DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.

Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.

Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.

Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high growth strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VETEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VETEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More